

Sun Pharmaceutical Industries Ltd.,

FORM D

(as prescribed by SEBI under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992
[Regulation 13(4) and (6)])

Regulation 13(6) — Details of change in shareholding by Director or Officer of a listed Company and his dependents

Company Name : Sun Pharmaceutical Industries Limited

Name, PAN No. & Address of Officer	No. & % of shares/ voting rights held by the Officer	Date of receipt of allotment advice/acquisition sale of shares	Date of intimation to company	Mode of sale acquisition (market purchase/ public/ rights/ preferential offer etc.)	No. & % of shares /post acquisition /voting rights sale-	Trading member through whom the trade was executed with SEBI Registration No. of the TM	Exchange on which the trade was executed	Buy quantity	Buy value	Sell quantity	Sell Value Rs. (Net)
Sadhana K. Ganorkar PAN No. AKKPG5544K Address Flat No. A/402 – Lakshachandi Heights, Krishnavatika Marg, Gokuldham, Goregaon (East) Mumbai 400 063	795 & % Negligible	08.10.2012	09.10.2012	Market sale	45 & % Negligible	Ventura Securities Ltd. SEBI Regn No. INB010760438	BSE	N.A.	N.A.	750	Rs.5,29,721.00

For Sun Pharmaceutical Industries Ltd.,

Ashok Bhuta
Compliance Officer

Date: 10.10.2012

October 10, 2012

1. National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
2. Bombay Stock Exchange Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Re: Disclosure under Regulation 13 (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Pursuant to the Regulation 13 (6) of the SEBI (Prohibition of Insider Trading) Regulations 1992, this is to inform you that the Company has received the disclosure in Form D under Regulation 13 (4) of the SEBI (Prohibition of Insider Trading) Regulations 1992 from Mr. Kirti Ganorkar, designated employee of the Company, stating that his wife Ms.Sadhana K. Ganorkar has sold 750 Equity shares of the Company on 08.10.2012 and that after the aforesaid sale, her shareholding in the Company will be 45 Equity Shares (i.e 0.00% of the total paid up Equity Share capital of the Company).

Please find herewith the disclosure in the prescribed Form D under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations 1992, based on the disclosure received from Mr. Kirti Ganorkar, designated employee of the Company under Regulation 13 (4) of the SEBI (Prohibition of Insider Trading) Regulations 1992.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd.,

Ashok Bhuta
Compliance Officer

Encl: As above